

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Appraisal Determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

During the scoping process consultees noted that people with limited mobility and those who use dosette boxes may benefit from the technology. They also commented that consideration should be given to the suitability of the technology in intravenous drug users, pregnancy and breast feeding, renal dysfunction, liver dysfunction, thrombolysis and people with a history of bleeding because apixaban is contraindicated in many of these circumstances. It was agreed during the scoping process that the highlighted issues were not equalities issues and did not need to be addressed by the Committee.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No.

- | |
|--|
| 3. Have any other potential equality issues been identified by the |
|--|

Committee, and, if so, how has the Committee addressed these?

Not applicable.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Summary of Appraisal Committee's key conclusions states that no equalities issues were raised.

Approved by Programme Director (name): ...Meindert
Boysen.....

Date: 12/02/2015